During the first 18 months of the trial, we have made progress toward our objectives. The project goals have not been modified.
Our overall objective is to determine a clinically optimal dose and estimate the efficacy of propranolol in dogs with hemangiosarcoma when given as an adjunct to chemotherapy. Continue reading “Research Update CHF 02534 MY 2 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma”
Despite the wide availability of tick-borne disease panels at laboratories in the USA and abroad, most results from sick dogs are negative, which frustrates veterinarians and dog owners trying to reach a definitive diagnosis. Continue reading “Research Update CHF 02528 MY2: Developing a Next Generation Sequencing Diagnostic Platform for Tick-Borne Diseases”
Hypoadrenocorticism or Addison’s disease (AD) consists of a life-threatening clinical condition that afflicts multiple purebred and mixed breed dogs. The condition results from autoimmune destruction of the adrenal glands leading to life-long cortisol deficiency. Similarly, another autoimmune condition causing pain and suffering to dogs is Symmetrical Lupoid Onychodystrophy (SLO). Continue reading “Research Update CHF 02488 Final: Addison’s Disease and Symmetrical Lupoid Onychodystrophy in Bearded Collies Provide Common Ground for Identifying Susceptibility Loci Underlying Canine Autoimmune Disorders”
Canine epilepsy is a chronic neurological condition, often requiring lifelong medication with anti-epileptic drugs (AEDs). Despite appropriate treatment with available AEDs, seizure freedom may not always be achievable. There is an urgent need to develop alternative treatments to improve the quality of life (QoL) of drug-resistant patients, who may continue to experience unpleasant AED side- effects despite their lack of success. Continue reading “Research Update CHF 02252 Final: Investigating a Ketogenic Medium-Chain Triglyceride (MCT) Supplement for the Treatment of Drug-Resistant Canine Idiopathic Epilepsy and Its Behavioral Comorbidities”
We enrolled 30 dogs with mild to moderate atopic dermatitis and 30 healthy control animals in the study. The dogs with atopic dermatitis were treated with either Apoquel® (n=17) or Cytopoint® (n=10), whereas one dog was switched from Apoquel® to Cytopoint®, one dog was treated with prednisone followed by Apoquel®, and one dog was treated with a topical shampoo. Continue reading “Research Update CHF 02651 MY2: Discovery of Novel Biomarkers of Canine Atopic Dermatitis through Lipid Profiling”
We have completed a lot of the proposed work related to the effects of CBD on cell death and autophagy and the upregulation of the MAP kinase pathway which appears to be involved, however the main mechanism of apoptosis has not been elucidated which may just be directly related to the autophagy induction. Continue reading “Research Update CHF 02643-A MY2: Examination of the Effects of Cannabidiol on Canine Neoplastic Cell Apoptosis/Autophagy and Potential for Chemotherapy Resistance or Sensitivity”
We have met our recruitment trajectory for this study over the past six months. We will continue to work hard to recruit additional dogs over the coming months and genotype the remaining dogs needed for the study as long as the genotyping service remains open under the Covid-19 pandemic. Public engagement with the project continues to be good. Continue reading “Research Update CHF 02624 MY2: Embracing Polygenicity of Common Complex Disease in Dogs: Genome-wide Association of Cruciate Ligament Rupture”
The preparations for the CBD epilepsy study were started in December 2017, including hiring a full[1]time research assistant and part-time work/study student, creating all of the study documents necessary for the trial, and creating a newsletter/announcement for Colorado veterinarians. We began enrolling patients for the study at the end of January 2018. Continue reading “Research Update CHF 02323 EY-3: Efficacy of Cannabidiol (CBD) for the Treatment of Canine Epilepsy”
Despite the wide availability of tick-borne disease panels at laboratories in the USA and abroad, most results from sick dogs are negative, which frustrates veterinarians and dog owners trying to reach a definitive diagnosis. Continue reading “Research Update CHF 02528 MY3: Developing a Next Generation Sequencing Diagnostic Platform for Tick-Borne Diseases”
The clinical response of dogs with lymphoma to multi-agent chemotherapy is highly variable. Although up to 85% of dogs respond initially, some relapse within weeks, while others enjoy remission times of two years. This heterogeneity in clinical response is in part explained by the recognition that “lymphoma” is not a single disease entity but consists of different subtypes that can be characterized on a molecular level by mutations in specific genes. Continue reading “Research Update CHF 02502 MY3: Precision Medicine for Canine Lymphoma”
